Review：Advances in monoclonal antibody application in myocarditis

• Published in: 浙江大学学报：B卷英文版 2013, Vol.14 (8), p.676-687
• Main Author: Li-na HAN Shuang HE Yu-tang WANG Li-ming YANG Si-yu LIU Ting ZHANG
• Format: Article
• Language: English
• Subjects: 临床; 冠状动脉; 心脏疾病; 调查结果
• ISSN: 1673-1581; 1862-1783

Monoclonal antibodies have become a part of daily preparation technologies in many laboratories. At- tempts have been made to apply monoclonal antibodies to open a new train of thought for clinical treatments of autoimmune diseases, inflammatory diseases, cancer, and other immune-associated diseases. This paper is a pro- spective review to anticipate that monoclonal antibody application in the treatment of myocarditis, an inflammatory disease of the heart, could be a novel approach in the future. In order to better understand the current state of the art in monoclonal antibody techniques and advance applications in myocarditis, we, through a significant amount of litera- ture research both domestic and abroad, developed a systematic elaboration of monoclonal antibodies, pathogenesis of myocarditis, and application of monoclonal antibodies in myocarditis. This paper presents review of the literature of some therapeutic aspects of monoclonal antibodies in myocarditis and dilated cardiomyopathy to demonstrate the advance of monoclonal antibody application in myocarditis and a strong anticipation that monoclonal antibody appli- cation may supply an effective therapeutic approach to relieve the severity of myocarditis in the future. Under con- ventional therapy, myocarditis is typically associated with congestive heart failure as a progressive outcome, indicating the need for alternative therapeutic strategies to improve long-term results. Reviewing some therapeutic aspects of monoclonal antibodies in myocarditis, we recently found that monoclonal antibodies with high purity and strong specificity can accurately act on target and achieve definite progress in the treatment of viral myocarditis in rat model and may meet the need above. However, several issues remain. The technology on how to make a higher homologous and weak immunogenic humanized or human source antibody and the treatment mechanism of monoclonal antibodies may provide solutions for these open issues. If we are to further stimulate progress in the area of clinical decision support, we must continue to develop and refine our understanding and use of monoclonal antibodies in myocarditis.